Abstract
The 5th edition of World Health Organization Classification of Haematolymphoid Tumours (WHO-HAEM5) is characterized by its hierarchical system for classification and novel entities/types. Considering the significant discrepancy in clinical manifestations and prognosis, fluid overload-associated large B-cell lymphoma (FOALBCL) has been a new addition to the WHO-HAEM5, being distinct from the traditional diagnosis of primary effusion lymphoma. In this manuscript, we report a patient who was diagnosed with FOALBCL, a novel entity introduced in the WHO-HAEM5. It is an instance of a successful application of the updated WHO-HAEM5 and indicates that the 'Blue Book' could confer convenience and benefits on both patients and clinicians. Moreover, the patient combined primary biliary cirrhosis (PBC), which is a relatively rare condition compared to the underlying medical condition of viral cirrhosis. Due to atypical clinical symptoms and invasive biopsy of lymphoma, sometimes, diagnoses might be undesired, which eventually leads to a poor prognosis. With this case report, it reminds not just hematologists but also other specialists to pay attention to the updates and revisions of the classifications of lymphoma.
Introduction: The Need for Precise Classification
In the world of hematology, precision in classification is the difference between over-treatment and life-saving care. For years, certain B-cell lymphomas presenting as fluid accumulation (effusions) in body cavities were grouped into ambiguous categories like "PEL-like lymphoma." This was problematic because Primary Effusion Lymphoma (PEL) is highly aggressive and usually linked to the Human Herpesvirus 8 (HHV8).
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours (WHO-HAEM5), released in 2022, introduced FOALBCL as a distinct entity. This paper addresses the clinical challenge of diagnosing this new entity in a complex patient presenting with ascites (fluid in the abdomen) and underlying primary biliary cirrhosis (PBC)—a much rarer precursor than the typical viral-induced cirrhosis.
Diagnostic Methodology
The authors utilized a multi-modal diagnostic approach to differentiate FOALBCL from more aggressive mimics:
- Imaging: Contrast-enhanced CT and full-body PET-CT were used to assess liver morphology and metabolic activity. Interestingly, the PET-CT showed no significant hypermetabolism, a key clue that the malignancy was not a typical high-grade aggressive lymphoma.
- Fluid Analysis: Biochemical analysis of the ascites fluid revealed abnormally high levels of lactate dehydrogenase (LDH).
- Cytology & Immunohistochemistry (IHC): Cells from the ascites and bone marrow were tested for specific markers including CD20, CD79α, and HHV8.
- Molecular Diagnostics: Fluorescence in situ hybridization (FISH) was employed to detect c-MYC gene amplification, a common driver in B-cell malignancies.
Key Insights and Clinical Results
The "Blue Book" Benefit
The paper demonstrates that the updated WHO classification (often called the "Blue Book") has immediate clinical utility. It allowed the team to move away from an ambiguous diagnosis to a specific one with a better prognosis. A critical finding was that the tumor cells were negative for KSHV/HHV8. While PEL is defined by the presence of this virus, FOALBCL is characteristically negative, occurring instead in the context of chronic fluid overload.
PBC as a Precursor
Most cases of fluid-associated lymphomas are linked to viral hepatitis or heart failure. This case identifies Primary Biliary Cirrhosis (PBC) as a potential underlying condition, expanding the clinical profile of who might be at risk for FOALBCL.
Diagnostic and Clinical Outcomes
- Markers: The lymphoma cells were confirmed as CD20+ and CD19+ (B-cell markers) but HHV8-negative, confirming the FOALBCL diagnosis over PEL.
- Genetics: FISH analysis revealed that 20%–30% of the cells in the ascites exhibited c-MYC amplification.
- Remission: The patient achieved symptomatic remission through peritoneal drainage and albumin supplementation alone, reinforcing that FOALBCL is less aggressive than PEL. Follow-up confirmed the patient remained alive and was tolerating chemotherapy well without the severe adverse effects often seen in PEL treatments.
Conclusion and Future Directions
While this single-patient case report validates the new WHO criteria, larger cohort studies are needed to fully define survival rates and optimal chemotherapy regimens for FOALBCL. There remains a slight discrepancy between the WHO-HAEM5 and the International Consensus Classification (ICC) guidelines regarding "provisional" entities. Future work should focus on harmonizing these international classifications to ensure that specialists outside of hematology, such as hepatologists, can easily recognize the signs of these rare lymphomas early.
Summary updated